Shilpi Mehrotra
Senior Project Manager, Chemicals and Materials
The opportunity is no longer theoretical
For decades, oral delivery of biologics was defined largely by what could not be done. Peptides and proteins face an unforgiving gastrointestinal environment: acid and enzymes can degrade them, while their size and polarity limit absorption across the intestinal wall. That scientific barrier has not disappeared, but the industry is learning to design around it.
Commercial successes now provide credible proof. Rybelsus, approved by the U.S. FDA in 2019, established that a GLP-1 peptide could be delivered as a tablet. More recently, oral semaglutide expanded into weight management, while Johnson & Johnson’s 2026 approval of ICOTYDE, a targeted oral peptide for plaque psoriasis, demonstrated that oral peptide innovation can extend beyond metabolic disease. These are not isolated milestones. Together, they signal that oral biologics are becoming a strategically relevant pharmaceutical segment.
Peptides are the beachhead, not the boundary
Peptides lead the current wave because they sit at a productive intersection of biological specificity and molecular engineerability. GLP-1 success has intensified interest, but the opportunity is widening into immunology, cardiovascular disease, endocrine disorders, and other chronic indications. Macrocyclic and constrained peptides are especially important because structural engineering can improve stability, permeability, and target selectivity.
The emerging landscape is also broader than one molecule type or one delivery principle. Programs are exploring proteins, antibodies, oligonucleotide-related modalities, and other complex therapeutics through approaches that range from permeation enhancement and enzyme protection to enteric systems, lipid-based delivery, nanoparticles, and device-enabled gastrointestinal administration. Not every modality will become a conventional tablet or capsule. Yet the direction is clear: oral delivery is evolving from a single-product achievement into a platform choice.
The formulation is becoming part of the asset
In oral biologics, the molecule alone rarely determines feasibility. The formulation must protect the active, release it at the right site, create a favourable local environment, and enable sufficient uptake without compromising safety, manufacturability, or dosage consistency. That makes formulation technology a source of competitive differentiation, not a downstream packaging decision.
For excipient suppliers, this changes the commercial question. Demand will not be driven only by the number of drugs launched. It will depend on the architecture selected for each product and the amount, grade, and functionality of every enabling ingredient. Absorption enhancers, protease inhibitors, pH modifiers, buffers, stabilizers, coatings, release-control polymers, fillers, binders, disintegrants, lubricants, capsule systems, and lipid-based ingredients will each play distinct roles. Specifications may also tighten around purity, consistency, regulatory documentation, and compatibility with sensitive biologic actives.
Bioprocessing demand will shift with the molecule mix
The opportunity begins much earlier than the final formulation. As oral biologics expand across peptides and more diverse modalities, the upstream and downstream manufacturing requirements of these biological active pharmaceutical ingredients (APIs) will also evolve. Each biological API brings unique fermentation, cell-culture, synthesis, purification, concentration, and stabilization needs. This can alter consumption patterns for cell-culture media components, amino acids, sugars, salts, buffers, surfactants, and other processing ingredients.
A credible demand view therefore cannot stop at counting pipeline assets. It must connect each drug to its ingredient requirements across production routes and formulation designs. Assessing ingredient demand for existing oral biologics, and expected volumes weighted by the probability of commercialization for pipeline products is critical. This can help suppliers distinguish a high-value functional opportunity from a large but weakly addressable headline market.
The partnership window is opening now
Recent investment activity underscores the urgency of evaluating the oral biologics landscape today. In 2026, Novo Nordisk and Vivtex announced a collaboration focused on oral biologics for obesity, diabetes, and related conditions, combining peptide and protein expertise with gastrointestinal screening and formulation technology. The strategic message is larger than one transaction: companies are actively assembling capabilities that they do not need to own alone.
Oral biologic development is inherently collaborative. Drug owners, delivery-platform companies, formulation specialists, CDMOs, excipient manufacturers, bioprocessing suppliers, and distributors can influence product feasibility well before launch. Early choices may shape platform adoption, supplier qualification, intellectual property positions, and long-term sourcing relationships. Once those relationships harden around successful platforms, late entrants may find that the most attractive opportunities are technically or commercially difficult to access.
From market excitement to actionable demand
The oral biologics opportunity is real, but it is not uniform. Success will depend on understanding where science, formulation, manufacturing, economics, and partnerships converge. Broad market forecasts alone will not reveal which ingredient categories will grow, how functionality requirements will change, or which companies are best positioned to capture value.
The next chapter of oral biologics will not be determined only by who develops the most promising molecule. It will also be shaped by who builds the right supply ecosystem for scaled production and formulation, before the window narrows.
Kline’s upcoming study, Excipients and Processing Ingredients in Oral Biopharmaceuticals: Global Opportunity Assessment, will connect the landscape from drug to demand. It will examine marketed and pipeline oral biologics, delivery technologies and platform owners, formulation construction, excipient and bioprocessing ingredient consumption, demand forecasts, and the competitive ecosystem. For ingredient suppliers, the objective is practical: clarity on where to innovate, whom to partner with, which customers to prioritize, and when to move.
